Long-term ligand activation of PPARα in mice causes hepatocarcinogenesis through a mechanism that requires functional PPARα. However, hepatocarcinogenesis is diminished in both -null and -humanized mice, yet both lines develop age-related liver cancer independently of treatment with a PPARα agonist. Since PPARα is a master regulator of liver lipid metabolism in the liver, lipidomic analyses were carried out in wild-type, -null, and -humanized mice treated with and without the potent agonist GW7647. The levels of hepatic linoleic acid in -null and -humanized mice were markedly higher compared to wild-type controls, along with overall fatty liver. The number of liver CD4 T cells was also lower in -null and -humanized mice and was negatively correlated with the elevated linoleic acid. Moreover, more senescent hepatocytes and lower serum TNFα and IFNγ levels were observed in -null and -humanized mice with age. These studies suggest a new role for PPARα in age-associated hepatocarcinogenesis due to altered lipid metabolism in -null and -humanized mice and the accumulation of linoleic acid as part of an overall fatty liver that is associated with loss of CD4 T cells in the liver in both transgenic models. Since fatty liver is a known causal risk factor for liver cancer, -null and -humanized mice are valuable models for examining the mechanisms of PPARα and age-dependent hepatocarcinogenesis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456914 | PMC |
http://dx.doi.org/10.3390/metabo13080936 | DOI Listing |
Background & Aims: Responses to immunotherapies in hepatocellular carcinoma (HCC) are suboptimal with no biomarkers to guide patient selection. "Humanized" mice represent promising models to address this deficiency but are limited by variable chimerism and underdeveloped myeloid compartments. We hypothesized that expression of human GM-CSF and IL-3 increases tumor immune cell infiltration, especially myeloid-derived cells, in humanized HCC patient-derived xenografts (PDXs).
View Article and Find Full Text PDFMedicina (Kaunas)
October 2024
Department of Pediatrics, West China Second Hospital, Sichuan University, Chengdu 610041, China.
Lancet Oncol
October 2024
Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy.
J Immunother Cancer
September 2024
Immunology and Immunotherapy, Centro de Investigación Médica Aplicada, Pamplona, Spain
Background: Immunodeficient mice engrafted with peripheral blood mononuclear cells (PBMCs) are models to study new cancer immunotherapy agents. However, this approach is associated with xenograft-versus-host disease (xGVHD), which starts early after PBMC transfer and limits the duration and interpretation of experiments. Here, we explore different approaches to overcome xGVHD and better support the development of cancer immunotherapies.
View Article and Find Full Text PDFSci Rep
September 2024
Division of Hematology-Oncology, Department of Internal Medicine, Chonnam National University Medical School and Hwasun Hospital, 322 Seoyang-Ro, Hwasun-Eup, Hwasun-Gun, Jeollanam-Do, 58128, Republic of Korea.
Preclinical drug efficacy and tumor microenvironment (TME) investigations often utilize humanized xenograft mouse models, yet these models typically fall short in replicating the intricate TME. We developed a humanized liver metastasis (LM) model by transplanting human peripheral blood mononuclear cells (PBMCs) and assessed it against the conventional subcutaneous (SC) xenograft model, focusing on immune cell dynamics post-transplantation and immunotherapy response. NOD-scid IL2Rgamma(NSG) were inoculated with PBMCs to create humanized models.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!